Hepatitis C | NASH

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Hepatitis C - The Silent Epidemic

Hepatitis C (HCV), often labeled a “silent epidemic,” is a serious blood-borne disease, affecting almost 110 million people worldwide. The major modes of transmission include blood transfusion, surgical or invasive procedures, and intravenous (IV) drug use.

HCV is largely asymptomatic for many years; people often do not know they are infected until the disease is in an advanced state.

It is a silent killer that lurks under the radar.

"Redefining Disease Management
Hepatitis C – 2014-2017 and Beyond"

This important collection of real-world insights is informed by scientifically validated, patient-reported, patient-experience data collected by Trio’s MDX platform.

If you are interested in downloading a copy of this book, please click here.

HCV Scientific Steering Committee

Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.

Nezam Afdhal, MD

Chairman – HCV Steering Committee
Professor of Medicine, Harvard Medical School
Beth Israel Deaconess Hospital (BIDMC) Boston, MA

Bruce Bacon, MD

James F. King, MD Endowed Chair in Gastroenterology at Saint Louis University (SLU), St. Louis, MO
Former President of the AASLD in 2004
Chair of the AASLD Foundation since 2013

Michael Curry, MD

Section Chief, Director of Liver Transplant, BIDMC, Boston MA
Associate Professor, Medicine, Harvard Medical School

Steven Flamm, MD

Professor of Medicine & Surgery, Division of Hepatology at Northwestern University, Chicago, IL
Chief of Transplantation Hepatology
Trustee of the AASLD Foundation

Naoky Tsai, MD

Private Practice – Honolulu, HI
Professor of Medicine – University of Hawaii

Zobair Younossi, MD, MPH

Chairman, Department of Medicine, Inova Fairfax Hospital, Fairfax, VA
Professor of Medicine, Virginia Commonwealth University
Chair of the Medical Advisory Committee of the National Capital Chapter of the ALF

COMMITTEE MEMBER ACCOMPLISHMENTS

Publication
Journals

Annals of Internal Medicine
APS - American Physiological Society
Clinical Gastroenterology
Journal of Hepatology
World Journal of Gastroenterology
The New England Journal of Medicine
Liver International

Associations
and Foundations

AASLD Foundation
American Board of Internal Medicine
ACG
ACP
AGA
American Liver Foundation
Hepatitis B Foundation
EASL
NIH

Advisory Board
Affiliations

AbbVie
AEVI
Angion
Bristol-Myers Squibb
Gilead
Ligand
Merck
Salix
Spring Bank

Publications & Abstracts

2022

Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease

Joana Vieira Barbosa, MD, MSc, Scott Milligan, PhD, Andrew Frick, MSc, Jeremy Broestl, BSc, Zobair Younossi, MD, MPH, Nezam H. Afdhal, MD, and Michelle Lai, MD, MPH

DOI: 10.14309/ajg.0000000000001606

Manuscript Published in: The American Journal of GASTROENTEROLOGY

Date of Publication: January 18, 2022

2021

Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD

Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, and Michelle Lai

DOI: 10.1002/hep4.1841

Manuscript Published in: Hepatology Communications

Date of Publication: December 30, 2021

The Impact of Race on NAFLD Outcomes in US Clinical Practice

Scott B. Minchenberg, Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Nezam H. Afdhal, and Michelle Lai

DOI: 10.1002/hep.32188:1747

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2021

Conference dates: November 12, 2021 - November 15, 2021

Multinational Evaluation of Comedication and Drug-drug Interactions in Hepatitis C Patients Treated with Pangenotypic Direct-acting Antivirals

Stefano Fagiouli, Scott Milligan, Juan Turnés, Alessandra Mangia, Andreas Hintz, Nicole Wick, Antoni Sicras, Luca DegliEsposti, Frank Tacke, Ramón Morillo, GemaAlvarez Nieto, GeroNiess, Stacey Scherbakovsky, MarinelaMéndez, Hsin-Jung Lin, Kim Vanstraelen, CandidoHernandez, and Tim Umland

Poster Presented at: Global Hepatitis Summit (GHS)

Conference dates: June 18, 2021 - June 20, 2021

Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antivrial Treatment Start? Results from a Large Multinational Real-world Dataset

Juan Turnés, Alessandra Mangia, Mandana Khalili, Scott Milligan, Stefano Fagiuoli, Vito Di Marco, George Papatheodoridis, Stanislas Pol, Silvia Rosati, AlnoorRamji, Elisabetta Teti, Lisa Barrett, Montserrat Garcia-Retortillo, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Elena Jiménez Mutilo, Luis Morano, Joss O’Loan, Francesca Campanale, Guilherme Macedo, Michele Milella, Christian Brixko, Maria Buti, Maria Fernanda Guerra Veloz, Roberto Ranieri, Sergio Borgia, Annalisa Bascià, ConradoM Fernandez-Rodriguez, Brian Conway, Victor De Lédinghen, Mary Fenech, Pablo Ryan, Ivana Maida, Alexandra Martins, Ioanna Ntalla, Hsin-Jung Lin, Candido Hernandez, Kim Vanstraelen, Stacey Scherbakovsky, and Stephen D Shafran

Global Hepatitis Summit 2020/2021; 2021 June 18-20

Poster Presented at: Global Hepatitis Summit (GHS)

Conference dates: June 18, 2021 - June 20, 2021

Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset

Alessandra Mangia, Silvia Rosati, Lisa Barrett, ElisabettaTeti, Montserrat Garcia-Retortillo, Elena Jiménez Mutilo, Francesca Campanale, Maria Buti, Maria Fernanda Guerra Veloz, Annalisa Bascià, Mary Fenech, Ivana Maida, Alexandra Martins, Juan Turnés, Scott Milligan, Stefano Fagiuoli, Vito Di Marco, Stephen D Shafran, George Papatheodoridis, Denis Ouzan, AlnoorRamji, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Luis Morano, Joss O’Loan, GuilhermeMacedo, Michele Milella, Christian Brixko, Roberto Ranieri, Sergio Borgia, ConradoM Fernandez-Rodriguez, Brian Conway, Victor De Lédinghen, Pablo Ryan, Stacey Scherbakovsky, Hsin-Jung Lin, Kim Vanstraelen, IoannaNtalla, Candido Hernandez, and Mandana Khalili

Global Hepatitis Summit 2020/2021; 2021 June 18-20

Poster Presented at: Global Hepatitis Summit (GHS)

Conference dates: June 18, 2021 - June 20, 2021

Eficacia de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con infección crónica por VHC y trastornos psiquiátricos: resultados en práctica clínica real en 6 países

García-Retortillo M, Milligan S, Barrett L, Teti E, Wedemeyer H, Fraser C, Morano L, Rodríguez-Tajes S, Acosta-López S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernández-Rodríguez CM, Martins Figueiredo L, Fenech M, Jiménez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Lédinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernández-López C, and Di Marco V

Gastroenterol Hepatol. 2021; 44 Supl Congr 2: 32-118: Abstract #64

Poster Presented at: Spanish Association for the Study of the Liver (AEEH)

Conference dates: June 14, 2021 - June 16, 2021

Prevalence of Drug-Drug Interactions with Pangenotypic Direct-Acting Antivirals for Hepatitis C and Real-World Care Management in the United States: A Retrospective Observational Study

Michael P Curry, MD, Steven L Flamm, MD, Scott Milligan, PhD, Naoky Tsai, MD, Nicole Wick, AS, Zobair Younossi, MD, and Nezam H Afdhal, MD

DOI: 10.18553/jmcp.2021.20550

Manuscript Published in: Journal of Managed Care + Specialty Pharmacy (JMCP)

Date of Publication: June 1, 2021

2020

Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic HCV Infection and Mental Health Disorders: Real-World Care Management from 8 Countries

Milligan S, Barrett L, Teti E, Garcia-Retortillo M, Wedemeyer H, Fraser C, Morano L, Rodriguez-Tajes S, Acosta-Lopez S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernandez-Rodriguez CM, Martins Figueiredo L, Fenech M, Jimenez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Ledinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernandez-Lopez C, and Di Marco V

Journal of Hepatology. November 2020; 72 (suppl 1): Abstract #905

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2020

Conference dates: November 13, 2020 - November 16, 2020

Association of FIB-4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU037

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU036

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #FRI107

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Dr. Michael P Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU435

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C

Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal

Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT387

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: August 27, 2020 - August 29, 2020

Global Real-World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective HCV Treatment: Analysis of 5552 Patients From 12 Cohorts

Alessandra Mangia, Scott Milligan, Mandana Khalili, Stefano Fagiuoli, Stephen D. Shafran, Fabrice Carrat, Denis Ouzan, George Papatheodoridis, Alnoor Ramji, Sergio M. Borgia, Heiner Wedemeyer, Ruggero Losappio, Francisco Perez-Hernandez, Nicole Wick, Robert S. Brown Jr., Pietro Lampertico, Karen Doucette, Ioanna Ntalla, Heribert Ramroth, Michael Mertens, Kim Vanstraelen, and Juan Turnes

DOI: 10.1111/liv.14537

Manuscript Published in: Liver International

Date of Publication: May 25, 2020

Evaluation of Liver Outcomes Relative to Use of GLP-1 Receptor Agonists (GLP1A) and/or SGLT-2 Inhibitors (SGLT2I) in Real-World Populations Diagnosed With Type II Diabetes (T2DM) and NASH/NAFLD or At Risk of NASH

Michelle Lai, Jeremy Broestl, Andrew Frick, Kavita Juneja, Scott Milligan, Zobair Younossi, and Nezam Afdhal

DOI: 10.1016/j.jval.2020.04.365

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020

Lean and Obese Patients With Non-Alcoholic Steatohepatitis (NASH) / Non-Alcoholic Fatty Liver Disease (NALFD); Comparisons of Populations and Disease Progression

Michelle Lai, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

DOI: 10.1016/j.jval.2020.04.363

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020

Real-World Effectiveness of Hepatitis C Virus (HCV) Treatment With Direct-Acting Antivirals (DAA) In Populations With Fatty Liver/Non-Alcoholic Steatohepatitis (FL/NASH), Decompensated Cirrhosis (DCC), Hepatocellular Carcinoma (HCC), and/or Post Liver Transplant (PTX)

Zobair Younossi, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal

DOI: 10.1016/j.jval.2020.04.478

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020

Real-World Effectiveness Of Direct-Acting Antivirals (DAA) In Young Adult (18-25) and Elderly (80+) Populations With Hepatitis C (HCV)

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

DOI: 10.1016/j.jval.2020.04.483

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2020 - May 20, 2020

Association of FIB-4 score with Major Cardiovascular Events (MACE) in real-world populations diagnosed with NASH or NAFLD in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

DOI: 10.1016/S0016-5085(20)33833-6

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: May 2, 2020 - May 5, 2020

Association of FIB4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal

DOI: 10.1016/S0016-5085(20)34210-4

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 2, 2020 - May 5, 2020

Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal

DOI: 10.1016/S0016-5085(20)34283-9

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 2, 2020 - May 5, 2020

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naıve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Steven L. Flamm, Jens Kort, Steven E. Marx, John Strezewski, Douglas E. Dylla, Bruce Bacon, Michael P. Curry, Naoky Tsai, and Nicole Wick

DOI: 10.1007/s12325-020-01301-5

Manuscript Published in: Advances in Therapy

Date of Publication: April 11, 2020

Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV

Sonia Vibhakar Patel, Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Janna RadtchenkoI, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn

DOI: 10.1371/journal.pone.0228847

Manuscript Published in: PLOS ONE

Date of Publication: February 13, 2020

Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic HCV Infection: A Meta-Analysis

Pietro Lampertico, Jose A. Carrion, Michael Curry, Juan Turnes, Markus Cornberg, Francesco Negro, Ashley Brown, Marcello Persico, Nicole Wick, Ariel Porcalla, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Hu, and Heiner Wedemeyer

DOI: 10.1016/j.jhep.2020.01.025

Manuscript Published in: Journal Of Hepatology

Date of Publication: February 12, 2020

2019

Real-world effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naive, noncirrhotic patients with HCV infection in the TRIO network

Michael P. Curry, Jens Kort, Steve Marx, John Strezewski, Nicole Wick, Steven L. Flamm, Bruce Bacon, and Naoky Tsai

Manuscript Published in: GastroHep Wiley

Date of Publication: November 23, 2019

Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Dr. Michael P. Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019

Conference dates: November 8, 2019 - November 12, 2019

Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C” – Poster of Distinction Award

Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P. Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019

Conference dates: November 8, 2019 - November 12, 2019

Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies

R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera

The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19

Poster Presented at: European AIDS Clinical Society (EACS)

Conference dates: November 6, 2019 - November 9, 2019

Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis

Markus Cornberg, Francesco Negro, Pietro Lampertico, Juan Turnes, Michael P Curry, Ashley Brown, Heiner Wedemeyer, Jose A. Carrion, Nicole Wick, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, and Marcello Persico

Poster Presented at: American College of Gastroenterology

Conference dates: October 25, 2019 - October 30, 2019

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

Naoky Tsai, MD, Bruce Bacon, MD, Michael Curry, MD, Steven L. Flamm, MD, Scott Milligan, PhD, Nicole Wick, AS, Zobair Younossi, MD, and Nexam Afhdal, MD

Manuscript Published in: American Journal of Managed Care (AJMC)

Date of Publication: July 12, 2019

Global Real World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective Regimen for the Treatment of Chronic Hepatitis C: Integrated Analysis of 12 Clinical Practice Cohorts

Dr. Alnoor Ramji, Dr. Alessandra Mangia, Dr. Scott Milligan, Prof. Mandana Khalili, Prof. Stefano Fagiuoli, Dr. Stephen D. Shafran, Prof. Fabrice Carrat, Prof. Denis Ouzan, Prof. George Papatheodoridis, Dr. Sergio M. Borgia, Prof. Heiner Wedemeyer, Valeria Piazzolla, Francisco Perez, Ms. Nicole Wick, Dr. Dawn Fishbein, Prof. Pietro Lampertico, Dr. Karen Doucette, Dr. Michael Mertens, Dr. Kim Vanstraelen, Dr. A. Anna Cumaraswamy, and Dr. Juan Turnes

Oral Presented at: Canadian Liver Meeting

Conference dates: May 24, 2019 - May 26, 2019

Access to HCV Cure Under Medicaid Programs in the United States

Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: April 10, 2019 - April 14, 2019

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019

Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion

The 54th Annual Meeting of the European Association for the Study of the Liver; 2019 Apr 10-14; Vienna, Austria

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019

Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019

Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network

Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019

2018

Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network

Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOF-VEL): Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network

Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai, and Nezam Afdhal

Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

The Impact of Individual Patient Data in a Network Meta-Analysis: An Investigation into Parameter Estimation and Model Selection

Joy Leahy, Aisling O'Leary, NEzam Afdhal, Emma Gray, Scott Milligan, Malte H. Wehmeyer, and Cathal Walsh

Manuscript Published in: Research Synthesis Methods

Date of Publication: June 20, 2018

Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Global Hepatitis Summit (GHS)

Conference dates: June 14, 2018 - June 17, 2018

Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0016-5085(18)33931-3

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer

DOI: 10.1016/S0016-5085(18)33670-9

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses from the TRIO Network

S.L. Flamm, B. Bacon, M. P. Curry, S. Milligan, C. U. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal

Manuscript Published in: Alimentary Pharmacology & Therapeutics (AP&T)

Date of Publication: April 17, 2018

Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018

Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0168-8278(18)30723-2

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018

Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion

DOI: 10.1016/S0168-8278(18)30735-9

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018

Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018

Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018

2017

Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017

Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network

M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017

HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network

Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017

Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017

Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network

C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017

Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)

C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017

Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017

Sofosbuvir/Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV

Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017

Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017

Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017

Sofosbuvir/Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV

Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017

Real-World Treatment Utilization and Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from The TRIO Network

S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017

Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017

Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network

Z. Younossi, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, and N. Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017

Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017

2016

Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Kris V. Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 11, 2016 - November 15, 2016

Real-World Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: the Trio Health Study

E. B. Tapper, B. R. Bacon, M. P. Curry, D. T. Dieterich, S. L. Flamm, L. E. Guest, K. V. Kowdley, Y. Lee, N. C. Tsai, Z. M. Younossi, and N. H. Afdhal

Manuscript Published in: Journal of Viral Hepatitis

Date of Publication: October 11, 2016

Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes With Ledipasvir and Sofosbuvir in a Real-World Cohort Study

Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry, Douglas T. Dieterich, Steven L. Flamm, Lauren E. Guest, Kris V. Kowdley, Yoori Lee, Naoky C. Tsai, Zobair M. Younossi, and Nezam H. Afdhal

Manuscript Published in: Hepatology

Date of Publication: August 17, 2016

Effectiveness of 8 or 12 week LDV/SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 21, 2016 - May 25, 2016

Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 21, 2016 - May 25, 2016

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016

Access to Therapy in Era of DAA Regimens: Real-World Experience from the TRIO Network

Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016

Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016

Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: International Liver Transplantation Society (ILTS)

Conference dates: May 4, 2016 - May 7, 2016

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2016 - April 17, 2016

Ledipasvir/Sofosbuvir+/-Ribavirin in HCV Post-Transplant Patients: Real-world Heterogeneous Population from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2016 - April 17, 2016

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients in the TRIO Network

Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2016 - April 17, 2016

Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: Asian Pacific Association for the Study of the Liver (APASL)

Conference dates: February 20, 2016 - February 24, 2016

Disparate Access to Treatment Regimens in Chronic Hepatitis C Patients: Data from The TRIO Network

Z. M. Younossi, B. R. Bacon, D. T. Dieterich, S. L. Flamm, K. Kowdley, S. Milligan, N. Tsai, and A. Nezam

Manuscript Published in: Journal of Viral Hepatitis

Date of Publication: February 3, 2016

2015

Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 13, 2015 - November 17, 2015

Effectiveness of 12 or 24 Week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 13, 2015 - November 17, 2015

Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Nezam Afdhal, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 13, 2015 - November 17, 2015

Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015

Evaluation of Access to Care in Patients Prescribed Sofosbuvir-Containing Regimens; Data from the TRIO Network

Zobair Younossi, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, and Naoky Tsai

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015

Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Douglas Dieterich, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015

Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients Over 70 Years; Data from the TRIO Network

Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 16, 2015 - May 19, 2015

Final Evaluation of HCV Patients Treated With 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Soctt Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 22, 2015 - April 26, 2015

Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network

Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 22, 2015 - April 26, 2015

Efficacy Evaluation of 24-Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 22, 2015 - April 26, 2015

2014

Evaluation of Sofosbuvir and Olysio-Based Regimens in the Trio Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

D Dieterich, B Bacon, S Flamm, K Kowdley, S Milligan, N Tsai, Z Younossi, and E Lawitz

Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 7, 2014 - November 11, 2014

Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network

Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Naoky Tsai

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 7, 2014 - November 11, 2014

Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network

Steven Flamm, Bruce Bacon, Douglas Dieterich, Kris Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, and Zobair Younossi

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 7, 2014 - November 11, 2014

Hepatitis C | NASH

​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Hepatitis C - The Silent Epidemic

HCV Scientific Steering Committee

Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.

Nezam Afdhal, MD

Bruce Bacon, MD

Michael Curry, MD

Steven Flamm, MD

Naoky Tsai, MD

Zobair Younossi, MD, MPH

COMMITTEE MEMBER ACCOMPLISHMENTS

PublicationJournals

Associationsand Foundations

Advisory BoardAffiliations

Publications & Abstracts

2022

Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease

2021

Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD

The Impact of Race on NAFLD Outcomes in US Clinical Practice

Multinational Evaluation of Comedication and Drug-drug Interactions in Hepatitis C Patients Treated with Pangenotypic Direct-acting Antivirals

Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antivrial Treatment Start? Results from a Large Multinational Real-world Dataset

Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset

Eficacia de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con infección crónica por VHC y trastornos psiquiátricos: resultados en práctica clínica real en 6 países

Prevalence of Drug-Drug Interactions with Pangenotypic Direct-Acting Antivirals for Hepatitis C and Real-World Care Management in the United States: A Retrospective Observational Study

2020

Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic HCV Infection and Mental Health Disorders: Real-World Care Management from 8 Countries

Association of FIB-4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice

Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice

Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C

Global Real-World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective HCV Treatment: Analysis of 5552 Patients From 12 Cohorts

Evaluation of Liver Outcomes Relative to Use of GLP-1 Receptor Agonists (GLP1A) and/or SGLT-2 Inhibitors (SGLT2I) in Real-World Populations Diagnosed With Type II Diabetes (T2DM) and NASH/NAFLD or At Risk of NASH

Lean and Obese Patients With Non-Alcoholic Steatohepatitis (NASH) / Non-Alcoholic Fatty Liver Disease (NALFD); Comparisons of Populations and Disease Progression

Real-World Effectiveness of Hepatitis C Virus (HCV) Treatment With Direct-Acting Antivirals (DAA) In Populations With Fatty Liver/Non-Alcoholic Steatohepatitis (FL/NASH), Decompensated Cirrhosis (DCC), Hepatocellular Carcinoma (HCC), and/or Post Liver Transplant (PTX)

Real-World Effectiveness Of Direct-Acting Antivirals (DAA) In Young Adult (18-25) and Elderly (80+) Populations With Hepatitis C (HCV)

Association of FIB-4 score with Major Cardiovascular Events (MACE) in real-world populations diagnosed with NASH or NAFLD in US Clinical Practice

Association of FIB4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice

Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naıve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV

Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic HCV Infection: A Meta-Analysis

2019

Real-world effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naive, noncirrhotic patients with HCV infection in the TRIO network

Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management

Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C” – Poster of Distinction Award

Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies

Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

Global Real World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective Regimen for the Treatment of Chronic Hepatitis C: Integrated Analysis of 12 Clinical Practice Cohorts

Access to HCV Cure Under Medicaid Programs in the United States

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the TRIO Network

Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network

2018

Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network

Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network

Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOF-VEL): Data from the TRIO Network

Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network

Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network

The Impact of Individual Patient Data in a Network Meta-Analysis: An Investigation into Parameter Estimation and Model Selection

Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network

Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network

Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses from the TRIO Network

Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network

Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Publication
Journals

Associations
and Foundations

Advisory Board
Affiliations